Total Valuation
Corbus Pharmaceuticals has a market cap or net worth of €166.94M. The enterprise value is €68.37.
Market Cap€166.94M
Enterprise Value€68.37
Share Statistics
Corbus Pharmaceuticals has 19,341,293 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding19,341,293
Owned by Insiders15.09%
Owned by Institutions41.40%
Financial Efficiency
Corbus Pharmaceuticals’s return on equity (ROE) is -0.53 and return on invested capital (ROIC) is -57.20%.
Return on Equity (ROE)-0.53
Return on Assets (ROA)-0.47
Return on Invested Capital (ROIC)-57.20%
Return on Capital Employed (ROCE)-0.58
Revenue Per Employee0.00
Profits Per Employee-2.18M
Employee Count36
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Corbus Pharmaceuticals is ―. Corbus Pharmaceuticals’s PEG ratio is -0.02.
PE Ratio―
PS Ratio0.00
PB Ratio0.73
Price to Fair Value0.73
Price to FCF-1.68
Price to Operating Cash Flow-2.24
PEG Ratio-0.02
Income Statement
In the last 12 months, Corbus Pharmaceuticals had revenue of 0.00 and earned -78.54M in profits. Earnings per share was -5.90.
Revenue0.00
Gross Profit0.00
Operating Income-85.31M
Pretax Income-78.54M
Net Income-78.54M
EBITDA-78.30M
Earnings Per Share (EPS)-5.90
Cash Flow
In the last 12 months, operating cash flow was -86.67M and capital expenditures -19.00K, giving a free cash flow of -86.69M billion.
Operating Cash Flow-86.67M
Free Cash Flow-86.69M
Free Cash Flow per Share-4.48
Dividends & Yields
Corbus Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.94
52-Week Price Change14.93%
50-Day Moving Average7.61
200-Day Moving Average7.64
Relative Strength Index (RSI)55.84
Average Volume (3m)98.00
Important Dates
Corbus Pharmaceuticals upcoming earnings date is Nov 10, 2026, TBA (Confirmed).
Last Earnings DateAug 6, 2026
Next Earnings DateNov 10, 2026
Ex-Dividend Date―
Financial Position
Corbus Pharmaceuticals as a current ratio of 8.07, with Debt / Equity ratio of 4.17%
Current Ratio8.07
Quick Ratio8.07
Debt to Market Cap0.00
Net Debt to EBITDA0.34
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Corbus Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Corbus Pharmaceuticals EV to EBITDA ratio is -1.04, with an EV/FCF ratio of -1.26.
EV to Sales0.00
EV to EBITDA-1.04
EV to Free Cash Flow-1.26
EV to Operating Cash Flow-1.26
Balance Sheet
Corbus Pharmaceuticals has €117.94M in cash and marketable securities with €4.26M in debt, giving a net cash position of €113.68M billion.
Cash & Marketable Securities€117.94M
Total Debt€4.26M
Net Cash€113.68M
Net Cash Per Share€5.88
Tangible Book Value Per Share€11.08
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Corbus Pharmaceuticals is €32.73, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target€32.73
Price Target Upside326.14% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast―
EPS Growth Forecast-21.12%